Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Sep 11;5(1):HEP10.
doi: 10.2217/hep-2018-0005. eCollection 2018 Jan.

Molecular heterogeneity in hepatocellular carcinoma

Shijia Zhu  1 , Yujin Hoshida  1
Affiliations
Editorial

Molecular heterogeneity in hepatocellular carcinoma

Shijia Zhu et al. Hepat Oncol. .
No abstract available

Keywords: clinical trial; hepatocellular carcinoma; molecular classification; molecular targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure Y Hoshida is supported by NIH/NIDDK DK099558, European Union ERC-2014-AdG-671231 HEPCIR, Irma T Hirschl Trust, US Department of Defense W81XWH-16-1-0363. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. - PubMed
    1. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. - PubMed
    1. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018;379(1):54–63. - PMC - PubMed
    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (checkmate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. - PMC - PubMed
    1. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (keynote-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. - PubMed

Publication types

LinkOut - more resources